company_name|source_name|scraping_datetime|article_url|article_datetime|article_title|article_text
CSX|scrape_standardized_cnbc|2020-10-16 15:26:46|https://www.cnbc.com/2019/07/17/stocks-making-the-biggest-moves-midday-csx-nu-skin-ralph-lauren-seattle-genetics-more.html?&qsearchterm=CSX|Published Wed, Jul 17 201912:59 PM EDT|Stocks making the biggest moves midday: CSX, Nu Skin, Ralph Lauren, Seattle Genetics & more|Check out the companies making headlines midday on Wednesday:CSX — CSX dropped 10.3% after the transportation company’s second-quarter earnings missed estimates and it cut its revenue forecast. CSX reported earnings of $1.08 on revenue of $3.06 billion. Analysts surveyed by Refinitiv were expecting earnings per share of $1.11 on revenue of $3.14 billion. CSX executives say the company’s disappointing second-quarter earnings were due to a “softer industrial environment.”Cintas — Shares of Cintas, which manufactures uniforms, jumped 8.7% to a new 52-week high profits topped estimates. The company’s results were driven by strong organic revenue growth in uniforms and First Aid kits.Bank of New York Mellon — The New York-based bank reported better-than-expected earnings for the second quarter, sending its stock up 2.3%. Bank of New York Mellon posted earnings per share of $1.01 while analysts polled by Refinitv expected a profit of 95 cents per share. The company’s results were driven by stronger-than-forecast fee revenue.Comerica — Comerica shares slid 3.6% after the bank reported weaker-than-forecast quarterly numbers. The company posted earnings per share of $1.94 on revenue of $853 million. Analysts expected a profit of $2 per share on sales of $859 million. A lower-than-expected net interest income weighed on Comerica’s results.Abbott Laboratories — The healthcare company’s stock gained 3.1% after it raised earnings guidance. The company expects earnings per share for fiscal 2019 to range between $3.21 per share and $3.27, up from a range of $3.15 and $3.25.Interactive Brokers — Shares of the online brokerage fell 2.8% after reporting disappointing 2019 Q2 earnings. The company’s second quarter earnings-per-share were 46 cents. Analysts polled by Refinitiv expected a profit of 53 cents per share. The company’s results were impacted by lower trading commissions and an 8% rise in expenses.Seattle Genetics — Seattle Genetics rose 18.9% as investors cheered record sales of Adcetris, a drug used to treat Hodgkin’s lymphoma. The company said Adcetris generated $159 million in U.S. and Canada sales. The Adcetris overshadowed mixed quarterly results. Piper Jaffray raised the company’s stock to overweight from neutral, citing the drug’s strong performance.Nu Skin Enterprises — Shares of Nu Skin Enterprises plunged 14.6%, hitting a new 52-week low, after the health and beauty products distributor said China’s crackdown on health products is weighing on sales. The company pre-announced disappointing second-quarter results and slashed its full-year 2019 earnings forecast.Levi Strauss — Shares of Levi Strauss dropped 4.6% after the apparel company was downgraded by Goldman Sachs to sell from neutral. The bank cited a high valuation relative to peers and skepticism that the denim company could expand its margins.Farfetch — An analyst at BTIG initiated Farfetch with a buy rating and a $26 price target, sending the stock up 4.4%. The analyst cited “ample avenues” for the luxury goods retailer to expand it total addressable market.Ralph Lauren — Ralph Lauren shares fell 3.8% after Goldman Sachs downgraded the clothing company to sell from neutral, citing headwinds in the company’s core North American market and “brand-specific challenges.”Redfin — Redfin shares rose 2.7% after an analyst at Susquehanna upgraded the real estate company to positive from neutral, citing an “attractive” risk/reward trade off.Bank of America — The bank’s stock rose 0.7% on stronger-than-expected second-quarter results that were driven by the company’s retail banking operation. Bank of America posted a profit of 74 cents per share on revenue of $23.23 billion. Analysts polled by Refinitiv expected earnings of 71 cents and sales of $23.195 billion.—CNBC’s Marc Rod, Mallika Mitra, Elizabeth Myong and Jesse Pound contributed to this report.
